Q-omics provides the consensus-scored ANAPC15 profile across patient tissues and cancer cell-line models. ANAPC15 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ANAPC15 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, ANAPC15 RNA expression shows 18,328 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, THCA, and ACC as cancer lineages where ANAPC15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANAPC15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANAPC15 survival associations across molecular data types. ANAPC15 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANAPC15 RNA expression–survival associations across cancer types. High ANAPC15 expression shows unfavorable associations in LIHC, ACC, KICH and HNSC, but favorable associations in BLCA and SKCM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ANAPC15 RNA expression.
This table summarizes ANAPC15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ANAPC15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANAPC15 shows lower tumor expression in THCA, KIRC and READ and higher tumor expression in LIHC, HNSC and CHOL. The THCA box plot shows higher ANAPC15 RNA expression in normal versus tumor tissue (log2 FC = −0.985, t-test p < 0.001).
This table shows molecular features associated with ANAPC15 in patient tissues and cancer cell lines. In patient samples, ANAPC15 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ANAPC15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SKIN.
